DiaSorin has launched a molecular assay for the rapid detection and quantification of cytomegalovirus (CMV). The DiaSorin Iam CMV assay is used to detect and quantify clinically relevant subtypes of CMV in human plasma, urine and cerebrospinal fluid (CSF), making it suitable for the diagnosis and monitoring of CMV infection in transplant recipients and other immunocompromised individuals.
The assay has good intra-run precision (≤0.3 log cps/mL) and diagnostic sensitivity (≥97%) and specificity (100%) said to be comparable to conventional PCR, but with results in a fraction of the time. In addition to being used for the detection and monitoring of CMV infection in immunocompromised individuals, the product is also used in the diagnosis of maternal and foetal CMV infection in early pregnancy and for monitoring CMV infection in affected babies. It is CE marked in accordance to IVD Medical Device Directive 98/79 CE.
Based on DiaSorin Q-LAMP technology, Iam CMV is the latest infectious disease assay for use on the DiaSorin Liaison Iam analyser. The small footprint, ease of use and scalable design of the benchtop instrument make it suitable for use in laboratory facilities of all sizes, including those that are located close to the patient.
Phone: 02 9338 4888
Maxwell Biosystems MaxTwo high-density microelectrode array (HD-MEA) system
The next-generation multiwell HD-MEA captures high-quality signals at subcellular resolution from...
Enzo Life Sciences PROTEOSTAT Protein refolding and aggregation sensing kit
The kit includes a comprehensive set of optimised screening reagents and conditions that...
Bio-Rad Laboratories ddPLEX ESR1 Mutation Detection Kit
The kit enables simultaneous detection, discrimination and absolute quantification of seven known...
